Associations of fish oil with cardiovascular disease events: results from the Taiwan longitudinal study in aging.
Cardiovascular event
Diabetes
Fish oil
Longitudinal study
Stroke
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
24 Jul 2024
24 Jul 2024
Historique:
received:
22
05
2024
accepted:
17
07
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
25
7
2024
Statut:
epublish
Résumé
The effectiveness of fish oil in preventing cardiovascular events is still debating. Some studies indicate a correlation between the use of fish oil supplements and reduced mortality or decreased incidence of stroke. However, other studies show no significant association between fish oil intake and stroke prevention, indicating an ongoing debate. This study aimed at exploring which subjects may benefit more from fish oil supplementation. This study utilized the data obtained through face-to-face interview from the Taiwan Longitudinal Study in Aging (TLSA). A total of 3,652 participants were included from the 2003 baseline data, after excluding patients with pre-existing ischemic heart disease or stroke. Participants were divided into two groups based on whether taking fish oil supplement or not. Participants were followed until 2015, estimating and comparing the all-cause mortality and cumulative incidence rate of stroke between both groups. The results of the 12-year longitudinal study showed that the cumulative incidence rate of stroke in the fish oil supplementation group was 5.7%, compared to 7.7% in the non-supplemented group (P < 0.05). Additionally, the crude hazard ratio for stroke was significantly lower in the fish oil supplementation group (HR = 0.686;95% CI 0.476-0.987). However, after adjusting potential confounders, the adjusted risk of stroke was lower only for the diabetic patients supplemented with fish oil (aHR = 0.123; 95% CI 0.016-0.930) compared to non-diabetic patients (aHR = 0.917; 95% CI 0.616-1.364). This study suggests that there is an association between fish oil supplementation and a lower cumulative incidence rate of subsequent stroke among diabetic patients.
Sections du résumé
BACKGROUND
BACKGROUND
The effectiveness of fish oil in preventing cardiovascular events is still debating. Some studies indicate a correlation between the use of fish oil supplements and reduced mortality or decreased incidence of stroke. However, other studies show no significant association between fish oil intake and stroke prevention, indicating an ongoing debate. This study aimed at exploring which subjects may benefit more from fish oil supplementation.
METHODS
METHODS
This study utilized the data obtained through face-to-face interview from the Taiwan Longitudinal Study in Aging (TLSA). A total of 3,652 participants were included from the 2003 baseline data, after excluding patients with pre-existing ischemic heart disease or stroke. Participants were divided into two groups based on whether taking fish oil supplement or not. Participants were followed until 2015, estimating and comparing the all-cause mortality and cumulative incidence rate of stroke between both groups.
RESULTS
RESULTS
The results of the 12-year longitudinal study showed that the cumulative incidence rate of stroke in the fish oil supplementation group was 5.7%, compared to 7.7% in the non-supplemented group (P < 0.05). Additionally, the crude hazard ratio for stroke was significantly lower in the fish oil supplementation group (HR = 0.686;95% CI 0.476-0.987). However, after adjusting potential confounders, the adjusted risk of stroke was lower only for the diabetic patients supplemented with fish oil (aHR = 0.123; 95% CI 0.016-0.930) compared to non-diabetic patients (aHR = 0.917; 95% CI 0.616-1.364).
CONCLUSION
CONCLUSIONS
This study suggests that there is an association between fish oil supplementation and a lower cumulative incidence rate of subsequent stroke among diabetic patients.
Identifiants
pubmed: 39048951
doi: 10.1186/s12889-024-19512-8
pii: 10.1186/s12889-024-19512-8
doi:
Substances chimiques
Fish Oils
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1979Informations de copyright
© 2024. The Author(s).
Références
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, et al. 2019 ACC/AHA Guideline on the primary Prevention of Cardiovascular Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice guidelines. Circulation. 2019;140(11):e596–646.
pubmed: 30879355
pmcid: 7734661
Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JR. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet (London, England) 1978, 2(8081):117–119.
Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet (London England). 2010;376(9740):540–50.
doi: 10.1016/S0140-6736(10)60445-X
pubmed: 20638121
Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the management of ST-Segment Elevation Acute myocardial infarction of the European Society of Cardiology. Eur Heart J. 2008;29(23):2909–45.
doi: 10.1093/eurheartj/ehn416
pubmed: 19004841
Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, Erdman JW Jr., Kris-Etherton P, Goldberg IJ, Kotchen TA, et al. Revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. J Nutr. 2001;131(1):132–46.
doi: 10.1093/jn/131.1.132
pubmed: 11208950
Rimm EB, Appel LJ, Chiuve SE, Djoussé L, Engler MB, Kris-Etherton PM, Mozaffarian D, Siscovick DS, Lichtenstein AH. Seafood Long-Chain n-3 polyunsaturated fatty acids and Cardiovascular Disease: A Science Advisory from the American Heart Association. Circulation. 2018;138(1):e35–47.
doi: 10.1161/CIR.0000000000000574
pubmed: 29773586
pmcid: 6903778
DiNicolantonio JJ, O’Keefe JH. The benefits of Omega-3 Fats for stabilizing and remodeling atherosclerosis. Mo Med. 2020;117(1):65–9.
pubmed: 32158053
pmcid: 7023944
O’Keefe EL, Harris WS, DiNicolantonio JJ, Elagizi A, Milani RV, Lavie CJ, O’Keefe JH. Sea Change for Marine Omega-3s: randomized trials show Fish Oil reduces Cardiovascular events. Mayo Clin Proc. 2019;94(12):2524–33.
doi: 10.1016/j.mayocp.2019.04.027
pubmed: 31627938
Siscovick DS, Barringer TA, Fretts AM, Wu JH, Lichtenstein AH, Costello RB, Kris-Etherton PM, Jacobson TA, Engler MB, Alger HM, et al. Omega-3 polyunsaturated fatty acid (Fish Oil) supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory from the American Heart Association. Circulation. 2017;135(15):e867–84.
doi: 10.1161/CIR.0000000000000482
pubmed: 28289069
pmcid: 6903779
Lichtenstein AH, Appel LJ, Vadiveloo M, Hu FB, Kris-Etherton PM, Rebholz CM, Sacks FM, Thorndike AN, Van Horn L, Wylie-Rosett J. 2021 Dietary Guidance to improve Cardiovascular Health: A Scientific Statement from the American Heart Association. Circulation. 2021;144(23):e472–87.
doi: 10.1161/CIR.0000000000001031
pubmed: 34724806
Adams J, Sibbritt D, Lui CW, Broom A, Wardle J. {Omega}-3 fatty acid supplement use in the 45 and up study cohort. BMJ open 2013, 3(4).
Albert BB, Derraik JG, Cameron-Smith D, Hofman PL, Tumanov S, Villas-Boas SG, Garg ML, Cutfield WS. Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA. Sci Rep. 2015;5:7928.
doi: 10.1038/srep07928
pubmed: 25604397
pmcid: 4300506
Del Gobbo LC, Imamura F, Aslibekyan S, Marklund M, Virtanen JK, Wennberg M, Yakoob MY, Chiuve SE, Dela Cruz L, Frazier-Wood AC, et al. ω-3 polyunsaturated fatty acid biomarkers and Coronary Heart Disease: Pooling Project of 19 Cohort studies. JAMA Intern Med. 2016;176(8):1155–66.
doi: 10.1001/jamainternmed.2016.2925
pubmed: 27357102
pmcid: 5183535
Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Albert CM, Gordon D, Copeland T, et al. Marine n-3 fatty acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med. 2019;380(1):23–32.
doi: 10.1056/NEJMoa1811403
pubmed: 30415637
Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308(10):1024–33.
doi: 10.1001/2012.jama.11374
pubmed: 22968891
Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, Geleijnse JM, Rauch B, Ness A, Galan P, et al. Associations of Omega-3 fatty acid supplement Use with Cardiovascular Disease risks: Meta-analysis of 10 trials involving 77 917 individuals. JAMA Cardiol. 2018;3(3):225–34.
doi: 10.1001/jamacardio.2017.5205
pubmed: 29387889
Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet (London England). 1989;2(8666):757–61.
doi: 10.1016/S0140-6736(89)90828-3
pubmed: 2571009
Burr ML, Ashfield-Watt PA, Dunstan FD, Fehily AM, Breay P, Ashton T, Zotos PC, Haboubi NA, Elwood PC. Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr. 2003;57(2):193–200.
doi: 10.1038/sj.ejcn.1601539
pubmed: 12571649
Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2002;112(4):298–304.
doi: 10.1016/S0002-9343(01)01114-7
pubmed: 11893369
Bonds DE, Harrington M, Worrall BB, Bertoni AG, Eaton CB, Hsia J, Robinson J, Clemons TE, Fine LJ, Chew EY. Effect of long-chain ω-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA Intern Med. 2014;174(5):763–71.
doi: 10.1001/jamainternmed.2014.328
pubmed: 24638908
Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet (London England). 2007;369(9567):1090–8.
doi: 10.1016/S0140-6736(07)60527-3
pubmed: 17398308
Avanzini F, Marzona I, Baviera M, Barlera S, Milani V, Caimi V, Longoni P, Tombesi M, Silletta MG, Tognoni G, et al. Improving cardiovascular prevention in general practice: results of a comprehensive personalized strategy in subjects at high risk. Eur J Prev Cardiol. 2016;23(9):947–55.
doi: 10.1177/2047487315613664
pubmed: 26525065
Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309–18.
doi: 10.1056/NEJMoa1203859
pubmed: 22686415
Liang J, Wang CN, Xu X, Hsu HC, Lin HS, Lin YH. Trajectory of functional status among older Taiwanese: gender and age variations. Soc Sci Med. 2010;71(6):1208–17.
doi: 10.1016/j.socscimed.2010.05.007
pubmed: 20667642
pmcid: 3495238
Planning T. Survey of Health and Living Status of the Elderly in Taiwan: Questionnaire and Survey Design. Population Studies Center and Institute of Gerontology; 1989.
Amini M, Zayeri F, Salehi M. Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study 2017. BMC Public Health. 2021;21(1):401.
doi: 10.1186/s12889-021-10429-0
pubmed: 33632204
pmcid: 7905904
Sun J, Qiao Y, Zhao M, Magnussen CG, Xi B. Global, regional, and national burden of cardiovascular diseases in youths and young adults aged 15–39 years in 204 countries/territories, 1990–2019: a systematic analysis of global burden of Disease Study 2019. BMC Med. 2023;21(1):222.
doi: 10.1186/s12916-023-02925-4
pubmed: 37365627
pmcid: 10294522
Bots SH, Peters SAE, Woodward M. Sex differences in coronary heart disease and stroke mortality: a global assessment of the effect of ageing between 1980 and 2010. BMJ Global Health. 2017;2(2):e000298.
doi: 10.1136/bmjgh-2017-000298
pubmed: 28589033
pmcid: 5435266
Larsson SC, Burgess S. Causal role of high body mass index in multiple chronic diseases: a systematic review and meta-analysis of mendelian randomization studies. BMC Med. 2021;19(1):320.
doi: 10.1186/s12916-021-02188-x
pubmed: 34906131
pmcid: 8672504
Banks E, Joshy G, Korda RJ, Stavreski B, Soga K, Egger S, Day C, Clarke NE, Lewington S, Lopez AD. Tobacco smoking and risk of 36 cardiovascular disease subtypes: fatal and non-fatal outcomes in a large prospective Australian study. BMC Med. 2019;17(1):128.
doi: 10.1186/s12916-019-1351-4
pubmed: 31266500
pmcid: 6607519
Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016., et al. Lancet (London England). 2017;390(10100):1345–422.
Pirie K, Peto R, Reeves GK, Green J, Beral V. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. Lancet (London England). 2013;381(9861):133–41.
doi: 10.1016/S0140-6736(12)61720-6
pubmed: 23107252
Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of Alcohol Consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ (Clinical Res ed). 2011;342:d671.
doi: 10.1136/bmj.d671
Havranek EP, Mujahid MS, Barr DA, Blair IV, Cohen MS, Cruz-Flores S, Davey-Smith G, Dennison-Himmelfarb CR, Lauer MS, Lockwood DW, et al. Social determinants of Risk and outcomes for Cardiovascular Disease: A Scientific Statement from the American Heart Association. Circulation. 2015;132(9):873–98.
doi: 10.1161/CIR.0000000000000228
pubmed: 26240271
Wang T, Li Y, Zheng X. Association of socioeconomic status with cardiovascular disease and cardiovascular risk factors: a systematic review and meta-analysis. Z fur Gesundheitswissenschaften = J Public Health 2023:1–15.
Schmidt AM. Diabetes Mellitus and Cardiovascular Disease. Arteriosclerosis, thrombosis, and vascular biology 2019, 39(4):558–568.
Nestel PJ, Mori TA. Dietary patterns, dietary nutrients and cardiovascular disease. Rev Cardiovasc Med. 2022;23(1):17.
doi: 10.31083/j.rcm2301017
pubmed: 35092209
Li ZH, Zhong WF, Liu S, Kraus VB, Zhang YJ, Gao X, Lv YB, Shen D, Zhang XR, Zhang PD, et al. Associations of habitual fish oil supplementation with cardiovascular outcomes and all cause mortality: evidence from a large population based cohort study. BMJ (Clinical Res ed). 2020;368:m456.
Xun P, Qin B, Song Y, Nakamura Y, Kurth T, Yaemsiri S, Djousse L, He K. Fish consumption and risk of stroke and its subtypes: accumulative evidence from a meta-analysis of prospective cohort studies. Eur J Clin Nutr. 2012;66(11):1199–207.
doi: 10.1038/ejcn.2012.133
pubmed: 23031847
pmcid: 6063513
O’Keefe JH, Tintle NL, Harris WS, O’Keefe EL, Sala-Vila A, Attia J, Garg GM, Hure A, Bork CS, Schmidt EB, et al. Omega-3 blood levels and stroke risk: a pooled and harmonized analysis of 183 291 participants from 29 prospective studies. Stroke. 2024;55(1):50–8.
doi: 10.1161/STROKEAHA.123.044281
pubmed: 38134264
Standards of Medical Care in Diabetes-2016 Abridged for Primary Care Providers. Clin Diabetes: Publication Am Diabetes Association. 2016;34(1):3–21.
doi: 10.2337/diaclin.34.1.3
Huang PC, Cheng H, Su YT, Huang MC, Hsu CC, Hwang SJ, Shin SJ, Chang WT. Interaction among dietary n-3 and n-6 polyunsaturated fatty acid intake, fatty acid desaturase 2 genetic variants, and low-density lipoprotein cholesterol levels in type 2 diabetes patients. J Diabetes Invest. 2023;14(2):297–308.
doi: 10.1111/jdi.13944
Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58(20):2047–67.
doi: 10.1016/j.jacc.2011.06.063
pubmed: 22051327
Manson JE, Bassuk SS, Lee IM, Cook NR, Albert MA, Gordon D, Zaharris E, Macfadyen JG, Danielson E, Lin J, et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials. 2012;33(1):159–71.
doi: 10.1016/j.cct.2011.09.009
pubmed: 21986389
Hartweg J, Farmer AJ, Holman RR, Neil HA. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes. Diabetologia. 2007;50(2):250–8.
doi: 10.1007/s00125-006-0486-y
pubmed: 17119918
Xie J, Wang Z, Wang J, Feng W, Shan T, Jing S, Xiao S, Li W, Liu N, Liu Y. Intakes of omega-3 fatty acids and risks of all-cause and cause-specific mortality in people with diabetes: a cohort study based on NHANES 1999–2014. Acta Diabetol. 2023;60(3):353–62.
doi: 10.1007/s00592-022-02003-w
pubmed: 36527499